Washington, Sept 27: According to a new study a new molecular target in blood clot formation has been found which may help to reduce clotting without any excessive bleeding.

unveils a new molecular target for anti-platelet drugs, which may avoid the dangerous side-effects of the current drugs."

The study, led by Shafi Kuchay and Dr. Athar Chishti, was made at the University of Illinois at Chicago College of Medicine.

Washington, Sept 27: A researcher at Tel Aviv University’s Sackler School of Medicine has developed what could be a new weight-loss wonder drug, which not only quells the desire to consume fatty foods, but also has fewer side effects.

Dr. Nir Barak developed the drug in conjunction with the drug company Obecure.

The drug, called HistaleanTM, is based on betahistine, an approved drug used for the treatment of vertigo.

Washington, Sept 27 : A new research has revealed that patients with both Clostridium difficile infection (C-difficile) and inflammatory bowel disease (IBD) like Crohn’s disease or ulcerative colitis, are four times more likely to die than patients with just IBD or C difficile infection.

Clostridium difficile infection is the main cause of diarrhoea among patients, and in recent years, the numbers of new cases of the infection have been steadily increasing.